Emapalumab in Children with Primary Hemophagocytic Lymphohistiocytosis, PMID: 32374962
Emapalumab for the treatment of hemophagocytic lymphohistiocytosis, PMID: 32648854
Emapalumab for the treatment of relapsed/refractory hemophagocytic lymphohistiocytosis, PMID: 31537529
Emapalumab: First Global Approval, PMID: 30623346
Emapalumab, PMID: 31643285
Emapalumab, PMID: 30694625
Emapalumab in Primary Hemophagocytic Lymphohistiocytosis, PMID: 32757534
Emapalumab in Primary Hemophagocytic Lymphohistiocytosis. Reply, PMID: 32757535
COVID-19: Review on latest available drugs and therapies against SARS-CoV-2. Coagulation and inflammation cross-talking, PMID: 32569708
Novel Therapeutic Approaches to Familial HLH (Emapalumab in FHL), PMID: 33424859
Antibodies to watch in 2019, PMID: 30516432
Emapalumab for adult and pediatric patients with hemophagocytic lymphohistiocytosis, PMID: 33686916
Emapalumab treatment in an ADA-SCID patient with refractory hemophagocytic lymphohistiocytosis-related graft failure and disseminated bacillus Calmette-Guérin infection, PMID: 32817285
A novel disorder involving dyshematopoiesis, inflammation, and HLH due to aberrant CDC42 function, PMID: 31601675
Treatment of refractory hemophagocytic lymphohistiocytosis with emapalumab despite severe concurrent infections, PMID: 30617216
Successful treatment of secondary macrophage activation syndrome with emapalumab in a patient with newly diagnosed adult-onset Still's disease: case report and review of the literature, PMID: 32793731
Can emapalumab be life saving for refractory, recurrent, and progressive cytokine storm caused by COVID-19, which is resistant to anakinra, tocilizumab, and Janus kinase inhibitors, PMID: 34169908
Combined use of emapalumab and ruxolitinib in a patient with refractory hemophagocytic lymphohistiocytosis was safe and effective, PMID: 33754483
Adult haemophagocytic lymphohistiocytosis: a Review, PMID: 31943120
Afebrile S. aureus bacteremia in two patients with hemophagocytic lymphohistiocytosis receiving emapalumab/dexamethasone/etoposide, PMID: 33751768
Role of interferon-γ in immune-mediated graft failure after allogeneic hematopoietic stem cell transplantation, PMID: 30792213
The role of interferon-gamma and its signaling pathway in pediatric hematological disorders, PMID: 33484058
Antibodies to watch in 2018, PMID: 29300693
Estimating health state utilities in hemophagocytic lymphohistiocytosis, PMID: 33471193
Virus-triggered secondary hemophagocytic lymphohistiocytosis, PMID: 34096649
Thinking Beyond HLH: Clinical Features of Patients with Concurrent Presentation of Hemophagocytic Lymphohistiocytosis and Thrombotic Microangiopathy, PMID: 32447592
Genetic Deficiency of Interferon-γ Reveals Interferon-γ-Independent Manifestations of Murine Hemophagocytic Lymphohistiocytosis, PMID: 31400073
Antibodies to watch in 2017, PMID: 27960628
Case Report: Rapid Recognition and Immune Modulation of Secondary HLH Due to Disseminated HSV Infection, PMID: 34277520
Chronic Graft-Versus-Host-Disease-Related Polymyositis: a 17-Months-Old Child with a Rare and Late Complication of Haematopoietic Stem Cell Transplantation, PMID: 31934312
Clinical Management of Relapsed/Refractory Hemophagocytic Lymphohistiocytosis in Adult Patients: A Review of Current Strategies and Emerging Therapies, PMID: 33888986
Systemic and Nodular Hyperinflammation in a Patient with Refractory Familial Hemophagocytic Lymphohistiocytosis 2, PMID: 33570715
The Use of Biologic Modifiers as a Bridge to Hematopoietic Cell Transplantation in Primary Immune Regulatory Disorders, PMID: 34248986
T Cell-Epstein-Barr Virus-Associated Hemophagocytic Lymphohistiocytosis (HLH) Occurs in Non-Asians and Is Associated with a T Cell Activation State that Is Comparable to Primary HLH, PMID: 34173902
X-Linked Lymphoproliferative Disease Mimicking Multisystem Inflammatory Syndrome in Children-A Case Report, PMID: 34414143
Non-genotoxic conditioning facilitates hematopoietic stem cell gene therapy for hemophilia A using bioengineered factor VIII, PMID: 34141826
Emapalumab treatment in rheumatologic disease-associated hemophagocytic lymphohistiocytosis: a plain language summary., PMID:40528399
Management of Refractory Malignancy-Associated Hemophagocytic Lymphohistiocytosis in Adolescent Patients: A Case Series of Novel Therapeutics and Treatment Challenges., PMID:40407638
Case Report: Successful use of emapalumab in adult B-cell acute lymphoblastic leukemia experiencing severe neurotoxicity and hemophagocytic lymphohistiocytosis-like features after CAR-T cell therapy., PMID:40255392
Emapalumab for severe cytokine release syndrome in solid tumor CAR-T: a case report., PMID:40236652
Specific drugs for rare diseases in a province of eastern China under catalog management: from 2021 to 2023., PMID:40230685
Macrophage activation syndrome successfully treated with eculizumab and emapalumab: a case report., PMID:40196116
CXCL9 and IL-18: potential biomarkers for efficacy evaluation in refractory hemophagocytic lymphohistiocytosis treated with RED (ruxolitinib, emapalumab and dexamethasone)., PMID:40186662
Macrophage Activation Syndrome: Not Just for Rheumatologists Anymore., PMID:40133144
Comment on: Acute respiratory distress syndrome after emapalumab treatment in a child with severe Still's disease and lung involvement: a case report., PMID:40036577
Emapalumab in Patients With Macrophage Activation Syndrome Associated With Still's Disease: A Population Pharmacokinetic/Pharmacodynamic Analysis., PMID:39943917
Salvage treatment of AOSD-associated macrophage activation syndrome with bariticinib following conventional immunosuppressive therapy., PMID:39939513
Refractory MDA-5 dermatomyositis rapidly progressive interstitial lung disease successfully treated with emapalumab., PMID:39893100
Pediatric Transplant and Cellular Therapy Consortium RESILIENT Conference on Pediatric Chronic Graft-versus-Host Disease Survivorship after Hematopoietic Cell Transplantation: Part II. Organ Dysfunction and Immune Reconstitution Considerations for Children with Chronic Graft-versus-Host Disease after Hematopoietic Cell Transplantation., PMID:39855565
Low-dose emapalumab combined with chemotherapy for adult patients with Epstein-Barr virus-associated hemophagocytic lymphohistiocytosis., PMID:39719162
Malignancy-associated HLH: mechanisms, diagnosis, and treatment of a severe hyperinflammatory syndrome., PMID:39656557
Efficacy of emapalumab in the management of anti‑CD19 chimeric antigen receptor T‑cell therapy‑associated cytokine release syndrome: A report of two cases., PMID:39628826
Emapalumab for the Treatment of Immune-Mediated Graft Failure after HSCT., PMID:39627345
Cytokine testing and challenges for diagnostic and clinical monitoring use., PMID:39613111
Acute respiratory distress syndrome after emapalumab treatment in a child with severe Still's disease and lung involvement: a case report., PMID:39602784
Hemophagocytic lymphohistiocytosis: current treatment advances, emerging targeted therapy and underlying mechanisms., PMID:39511607
Emapalumab as a therapeutic intervention for Epstein-Barr virus-associated hemophagocytic lymphohistiocytosis: A case series., PMID:39331881
Efficacy and safety of therapies for Still's disease and macrophage activation syndrome (MAS): a systematic review informing the EULAR/PReS guidelines for the management of Still's disease., PMID:39317415
Systemic T-cell activation and IFN-γ activity in indeterminate severe hepatitis are reminiscent of hemophagocytic lymphohistiocytosis: Implications for T-cell- and IFN-γ-directed therapies., PMID:39278359
Emapalumab Treatment in Patients With Rheumatologic Disease-Associated Hemophagocytic Lymphohistiocytosis in the United States: A Retrospective Medical Chart Review Study., PMID:39245963
Emapalumab therapy for hemophagocytic lymphohistiocytosis before reduced-intensity transplantation improves chimerism., PMID:39190435
Salvage Therapy and Allogeneic Hematopoietic Cell Transplantation for the Severe Cytokine Storm Syndrome of Hemophagocytic Lymphohistiocytosis., PMID:39117843
Anti-Interferon-γ Therapy for Cytokine Storm Syndromes., PMID:39117840
Cytokine Storm and Sepsis-Induced Multiple Organ Dysfunction Syndrome., PMID:39117832
Current treatment in macrophage activation syndrome worldwide: a systematic literature review to inform the METAPHOR project., PMID:39058514
Successful Treatment of Severe Steroid-Resistant Engraftment Syndrome Following Haploidentical Allogeneic Hematopoietic Stem Cell Transplantation for Acute Myeloid Leukemia with Emapalumab: A Case Report., PMID:38855328
Inhibition of interferon gamma impairs induction of experimental epidermolysis bullosa acquisita., PMID:38799441
Emapalumab as salvage therapy for adults with malignancy-associated hemophagocytic lymphohistiocytosis., PMID:38752279
Case report: emapalumab treatment for a pediatric Epstein-Barr virus-associated hemophagocytic lymphohistiocytosis (EBV-HLH) patient with cytokine storm enabling allogeneic hematopoietic cell transplantation., PMID:38715677
Combined Use of Emapalumab With Ruxolitinib and Dexamethasone as an Effective Treatment for Epstein-Barr Virus-associated Hemophagocytic Lymphohistiocytosis Complicated With Multiorgan Damage and Severe Infection., PMID:38691058
Population Pharmacokinetics of the Anti-Interferon-Gamma Monoclonal Antibody Emapalumab: An Updated Analysis., PMID:38662147
Combined emapalumab and ruxolitinib in patients with haemophagocytic Lymphohistiocytosis., PMID:38658542
Does your unwell patient have haemophagocytic lymphohistiocytosis?, PMID:38557089
Real-world treatment patterns and outcomes in patients with primary hemophagocytic lymphohistiocytosis treated with emapalumab., PMID:38429096
Successful Treatment of Refractory EBV-Associated Hemophagocytic Lymphohistiocytosis with Combined Emapalumab and PD-1 Blockade., PMID:38400989
Case Report: Refractory macrophage activation syndrome requiring high-dose anakinra, emapalumab, and etoposide therapy in early-onset systemic juvenile idiopathic arthritis associated with adenoviremia., PMID:38322244
Case Report: Successful avoidance of etoposide for primary hemophagocytic lymphohistiocytosis-induced multiple organ dysfunction syndrome using emapalumab., PMID:38304439
Editorial: Emerging talents in primary immunodeficiencies: 2022., PMID:38077356
Exposure-safety relationship for patients with primary hemophagocytic lymphohistiocytosis treated with emapalumab., PMID:38014905
Survival in primary hemophagocytic lymphohistiocytosis, 2016 to 2021: etoposide is better than its reputation., PMID:37992218
Schuelke MR, Bassiri H, Behrens EM, et al. Emapalumab for the treatment of refractory cytokine release syndrome in pediatric patients. Blood Adv. 2023;7(18):5603-5607., PMID:37966846
Emapalumab for the treatment of refractory cytokine release syndrome in pediatric patients., PMID:37721859
Emapalumab as bridge to hematopoietic cell transplant for STAT1 gain-of-function mutations., PMID:37367708
Neutralizing IFNγ improves safety without compromising efficacy of CAR-T cell therapy in B-cell malignancies., PMID:37296093
For research use only. Not for human or drug use.
